2019
DOI: 10.1016/j.mce.2018.08.004
|View full text |Cite
|
Sign up to set email alerts
|

Role of hydroxysteroid (17beta) dehydrogenase type 1 in reproductive tissues and hormone-dependent diseases

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
2
1

Citation Types

0
11
1

Year Published

2020
2020
2023
2023

Publication Types

Select...
7

Relationship

0
7

Authors

Journals

citations
Cited by 18 publications
(12 citation statements)
references
References 256 publications
0
11
1
Order By: Relevance
“…The hydroxysteroid (17beta) dehydrogenase type 1 (HSD17B1) is a steroidogenic enzyme encoded by HSD17B1 gene, to efficiently catalyze reversible interconversion of a low-active precursor estrogen estrone (E1) to the highly active E2 that is necessary for normal ovary development [ 13 , 45 ]. It is the major isozyme in the granulosa cells of the ovary and has a central role in regulating the circulating estradiol concentration as well as its local production in estrogen target cells, locally promotes development, differentiation, and maturation of the follicle [ 46 48 ].…”
Section: Discussionmentioning
confidence: 99%
See 1 more Smart Citation
“…The hydroxysteroid (17beta) dehydrogenase type 1 (HSD17B1) is a steroidogenic enzyme encoded by HSD17B1 gene, to efficiently catalyze reversible interconversion of a low-active precursor estrogen estrone (E1) to the highly active E2 that is necessary for normal ovary development [ 13 , 45 ]. It is the major isozyme in the granulosa cells of the ovary and has a central role in regulating the circulating estradiol concentration as well as its local production in estrogen target cells, locally promotes development, differentiation, and maturation of the follicle [ 46 48 ].…”
Section: Discussionmentioning
confidence: 99%
“…Moreover, a plethora of ovarian paracrine and autocrine factors was involved in regulation of the follicle development and its function as well as the positive or negative controls through the endocrinal hormones from the hypothalamus and pituitary, including gonadotropin releasing hormone (GNRH), gonadotropin inhibitory hormone (GNIH), and follicle stimulating hormone (FSH) [ 1 , 2 , 8 ]. Within the ovary, the most representative hormones and growth factors such as steroidogenic-related enzymes steroidogenic acute regulatory protein (STAR), hydroxysteroid (17beta) dehydrogenase 1 (HSD17B1) and cytochrome P450 side-chain cleavage (P450scc/CYP11A1), intra-ovarian hormones progesterone (P4), estradiol (E2) and anti-müllerian hormone (AMH), cell proliferation or apoptosis-related factors Bcl-2, cyclin D1 (CCND1) and caspase-3 (CASP3), which have indispensable effects on follicular development, follicle selection or atresia, finally on their preovulatory development and ovulation, making the early developmental differences of ovarian follicles and egg production capacity in adult layers highly correlated, have been intensively investigated [ 9 13 ]. Undoubtedly, follicular size has a close relationship with its developmental biology, physiological function, and molecular regulation.…”
Section: Introductionmentioning
confidence: 99%
“…HSD17B1 contains 327 amino acids, with a subunit mass of 34.8 kDa, and is highly expressed in the placenta and ovaries. [ 31 ] In addition, HSD17B1 has an N‐terminal short‐chain dehydrogenase domain and a narrow hydrophobic C‐terminal domain that bind with a cofactor and steroid substrate, respectively. [ 32 ] We are currently noting an increasing number of studies on HSD17B1 inhibitors for the treatment of hormone‐dependent diseases, including endometriosis, breast cancers, and cervical cancer.…”
Section: Discussionmentioning
confidence: 99%
“…Due to their side effect profile, European (ESHRE) guidelines recommend they are used in combination with other drugs and not as a first line therapy (Dunselman et al, 2014). New Review generations of drugs that target other enzymes overexpressed in endometriosis lesions include those directed at 17betaHSD1 (Heinosalo et al, 2019), dual inhibitors of steroid sulfatase/17be-taHSD (Salah et al, 2017(Salah et al, , 2019, and AKR1C3 (Ri zner and Penning, 2020). Although a clinical trial for the 17ßHSD inhibitor FOR-6219 is underway (Table 3), trials with the AKR1C3 inhibitor BAY1128688 were terminated early due to reports of hepatotoxicity (NCT03373422).…”
Section: Llmentioning
confidence: 99%